Compare YieldMax NVDA Option Income Strategy ETF (NVDY) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax NVDA Option Income Strategy ETF vs Revvity Inc — how do they compare? YieldMax NVDA Option Income Strategy ETF trades at $12.64, while Revvity Inc trades at $124.14 (market cap $13.82B). The key difference: Revvity Inc pays a 0.23% dividend while YieldMax NVDA Option Income Strategy ETF pays none, and Revvity Inc is trading nearer its 52-week high, YieldMax NVDA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| NVDY | RVTY | |
|---|---|---|
Sector | Income / Options Overlay | Technology |
52-Week High | $17.21 | $130.94 |
52-Week Low | $11.58 | $82.26 |
Market Cap | — | $13.82B |
Enterprise Value | — | $16.14B |
Dividend Yield | — | 0.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVDY trades at $12.82, down 1.23% on the day, with a bullish technical signal from moving averages but neutral oscillators. The ETF generates weekly dividends, recently averaging $0.10 per distribution, but faces criticism for NAV erosion despite high yields. Recent news highlights downgrades to Hold due to diminished upside participation and falling option premiums.
Outlook remains cautious; high distribution rates come at the cost of long-term capital erosion, limiting attractiveness for growth investors. Risks include dependency on Nvidia's volatility and capped upside potential. Investors prioritizing income may find value, but total return prospects are constrained.
RVTY trades at $127.08, down 2.41% over 24 hours, with a bullish technical signal driven by moving averages and strong support at $126. The company reported Q2 2026 EPS of $1.41, beating estimates, and raised its full-year outlook, supported by diagnostics growth and improved cash flow. Recent news includes the acquisition of Human Cell Design and product launches, indicating strategic expansion.
Outlook remains positive with a consensus price target of $136.20, offering ~7% upside, but high P/E of 59.54 poses valuation risk. Key opportunities include earnings momentum and innovation; risks involve premium valuation and competitive pressures in the healthcare sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About YieldMax NVDA Option Income Strategy ETF
NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
